All Stories

  1. In vivo exposure to lipopolysaccharide inhibits STAT1 signaling
  2. Early Alzheimer´s disease blood biomarkers are associated with a higher risk for postoperative long‐term cognitive decline: Insights from the FINDERI study
  3. Evaluation of fully automated ApoE4 proteotyping for APOE ε4 genotype estimation in the FINDERI cohort
  4. Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies
  5. Amyloid Plaques Ameliorate Memory Deficits and Hippocampal Neuron Loss in an Aβ4-42-Driven Alzheimer’s Disease Mouse Model
  6. Characterization of a pathogenic gain-of-function mutation in the N-terminal domain of STAT1 which is reported to be associated with eosinophilic esophagitis
  7. Behavioral assessment and gene expression changes in a mouse model with dysfunctional STAT1 signaling
  8. N-terminal truncation of STAT1 transcription factor causes CD3- and CD20-negative non-Hodgkin lymphoma through upregulation of STAT3-mediated oncogenic functions
  9. Cognitive decline and neuroinflammation in a mouse model of obesity: An accelerating role of ageing
  10. Social inhibition in depressed patients is associated with an altered activation profile of the interleukin-6-inducible transcription factor STAT3
  11. Caffeine and potential use in Alzheimer’s disease
  12. Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia
  13. Apolipoprotein E aggregation in microglia initiates Alzheimer’s disease pathology by seeding β-amyloidosis
  14. Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice
  15. Amino‐terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains
  16. Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer’s disease
  17. Blood plasma biomarkers for Alzheimer’s disease: Aβ1–42/1–40 vs. AβX–42/X–40
  18. A novel interface between the N-terminal and coiled-coil domain of STAT1 functions in an auto-inhibitory manner
  19. Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease
  20. Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
  21. Lack of STAT1 co-operative DNA binding protects against adverse cardiac remodelling in acute myocardial infarction
  22. Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS
  23. A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model
  24. Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
  25. Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
  26. Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice
  27. An inhibitory effect on the nuclear accumulation of phospho-STAT1 by its unphosphorylated form
  28. Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer’s disease
  29. Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid
  30. Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis
  31. Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy
  32. The anti-parallel dimer binding interface in STAT3 transcription factor is required for the inactivation of cytokine-mediated signal transduction
  33. A microRNA signature that correlates with cognition and is a target against cognitive decline
  34. Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau
  35. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
  36. Physical activity and cognitive stimulation ameliorate learning and motor deficits in a transgenic mouse model of Alzheimer’s disease
  37. Alzheimer’s Disease
  38. Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
  39. Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
  40. Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer’s Disease
  41. Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples
  42. N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
  43. Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease
  44. Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
  45. N-Terminally Truncated Aß Peptide Variants in Alzheimer’s Disease
  46. N-Terminal Truncated Aβ4-42 Is a Substrate for Neprilysin Degradation in vitro and in vivo
  47. Physical Activity Ameliorates Impaired Hippocampal Neurogenesis in the Tg4-42 Mouse Model of Alzheimer’s Disease
  48. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
  49. The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease
  50. Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
  51. The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
  52. Synergistic Effect on Neurodegeneration by N-Truncated Aβ4−42 and Pyroglutamate Aβ3−42 in a Mouse Model of Alzheimer's Disease
  53. N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
  54. Altered neurogenesis in mouse models of Alzheimer disease
  55. Extraction of Soluble and Insoluble Protein Fractions from Mouse Brains and Spinal Cords
  56. Preparation of Crude Synaptosomal Fractions from Mouse Brains and Spinal Cords
  57. Effects of Long-Term Environmental Enrichment on Anxiety, Memory, Hippocampal Plasticity and Overall Brain Gene Expression in C57BL6 Mice
  58. Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model
  59. Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
  60. The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte DifferentiationIn Vitroand Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination
  61. Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer’s Disease
  62. Alzheimer’s Disease
  63. Immunotherapy Against N-Truncated Amyloid-β Oligomers
  64. Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer’s Disease
  65. N-Truncated Aβ2-X Starting with Position Two in Sporadic Alzheimer’s Disease Cases and Two Alzheimer Mouse Models
  66. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease
  67. Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease
  68. I716F AβPP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid-β and α-Synucleinopathy with Lewy Bodies
  69. Immunocytochemical Detection of Intraneuronal Aβ Peptides in Mouse Models of Alzheimer’s Disease
  70. Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation
  71. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease
  72. Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimer’s Disease by Deep Sequencing
  73. Aβ38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models
  74. Immunolesion-induced loss of cholinergic projection neurones promotes β-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice
  75. Abundance of Aβ5-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer’s disease
  76. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease
  77. Oligomeric Pyroglutamate Amyloid-β is Present in Microglia and a Subfraction of Vessels in Patients with Alzheimer's Disease: Implications for Immunotherapy
  78. N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
  79. Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias
  80. Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer’s disease
  81. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody
  82. Problems During Aging (Alzheimer’s and Others)
  83. The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ
  84. Intraneuronal Aβ accumulation and neurodegeneration: Lessons from transgenic models
  85. Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells
  86. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
  87. Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates
  88. AβPP Accumulation and/or Intraneuronal Amyloid-β Accumulation? The 3xTg-AD Mouse Model Revisited
  89. Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease
  90. Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice
  91. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease
  92. Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease
  93. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease
  94. Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?
  95. Overexpression of Glutaminyl Cyclase, the Enzyme Responsible for Pyroglutamate Aβ Formation, Induces Behavioral Deficits, and Glutaminyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice
  96. Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
  97. Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice
  98. Intracellular Aβ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease
  99. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease
  100. Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
  101. Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients
  102. Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-regulation of the Alzheimer Amyloid Precursor Protein
  103. Intracellular accumulation of amyloid-beta – a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease
  104. Neuron Loss in Transgenic Mouse Models of Alzheimer's Disease
  105. Formic acid is essential for immunohistochemical detection of aggregated intraneuronal Aβ peptides in mouse models of Alzheimer's disease
  106. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
  107. Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
  108. Circulating immune complexes of Aβ and IgM in plasma of patients with Alzheimer’s disease
  109. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
  110. Die modifizierte Amyloid-Hypothese der Alzheimer-Demenz – intraneuronales Abeta induziert Neurodegeneration
  111. Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice
  112. Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial
  113. Early Intraneuronal β-Amyloid Pathology: Do Transgenic Mice Represent Valid Model Systems?
  114. Alzheimer-Demenz
  115. Age-dependent loss of dentate gyrus granule cells in APP/PS1KI mice
  116. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease
  117. Motor impairment in Alzheimer’s disease and transgenic Alzheimer’s disease mouse models
  118. Review on the APP/PS1KI mouse model: intraneuronal Aβ accumulation triggers axonopathy, neuron loss and working memory impairment
  119. Intraneuronal β-Amyloid Is a Major Risk Factor – Novel Evidence from the APP/PS1KI Mouse Model
  120. Age-dependent axonal degeneration in an Alzheimer mouse model
  121. Altered cholesterol metabolism in APP695-transfected neuroblastoma cells
  122. Gender dependent APP processing in a transgenic mouse model of Alzheimer’s disease
  123. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer’s disease
  124. Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease
  125. OTX1 and OTX2 Expression Correlates With the Clinicopathologic Classification of Medulloblastomas
  126. Traumatic brain injury: cause or risk of Alzheimer’s disease? A review of experimental studies
  127. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade
  128. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice
  129. No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the β-cleaved C-terminal APP fragment
  130. α-Synuclein, Aβ and Alzheimer's disease
  131. Reelin in plaques of β-amyloid precursor protein and presenilin-1 double-transgenic mice
  132. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice